Literature DB >> 3812382

Rotavirus gastroenteritis. Clinical and laboratory features and use of the Rotazyme test.

A Kovacs, L Chan, C Hotrakitya, G Overturf, B Portnoy.   

Abstract

Clinical and laboratory features of 86 infants admitted with diarrhea and dehydration were evaluated prospectively. Human rotavirus (HRV) infection was documented in 35 infants (41%) by the Rotazyme test. Those with HRV gastroenteritis (HRV+ group) had a shorter duration of diarrhea prior to admission, more severe dehydration on presentation, and a longer hospital course than the HRV-negative (HRV-) group. Vomiting, fever, upper respiratory tract symptoms, otitis media, and cough were present in equal numbers of infants in both groups. The HRV+ infants had lower serum bicarbonate and higher serum albumin, alanine aminotransferase, aspartate aminotransferase, and uric acid concentrations than did the HRV- infants. Serum uric acid levels greater than 10 mg/dL (590 mumol/L) were present in 69% of HRV+ vs 29% of HRV- infants. The Rotazyme test was found to be a valuable tool in diagnosis; testing on two days increased the yield from 74% to 97% of all infants finally diagnosed as HRV+. The optimal time for testing was within the first five days of illness.

Entities:  

Mesh:

Year:  1987        PMID: 3812382     DOI: 10.1001/archpedi.1987.04460020051025

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  11 in total

Review 1.  Recognition and prevention of hospital-associated enteric infections in the intensive care unit.

Authors:  Linda D Bobo; Erik R Dubberke
Journal:  Crit Care Med       Date:  2010-08       Impact factor: 7.598

2.  Acute renal failure due to obstructive uric acid stones associated with rotavirus gastroenteritis.

Authors:  Shuichiro Fujinaga; Kazunari Kaneko; Yoshiyuki Ohtomo; Masaru Takada; Kenichiro Kobayashi; Minoru Tada; Yuichiro Yamashiro
Journal:  Pediatr Nephrol       Date:  2005-02       Impact factor: 3.714

3.  Cause of uric acid stones in rotavirus-associated gastroenteritis.

Authors:  Kazunari Kaneko; Tomohiko Shimo; Masato Hirabayashi; Taichi Ito; Hitoshi Okazaki; Yoshiaki Harada
Journal:  Pediatr Nephrol       Date:  2010-02-27       Impact factor: 3.714

4.  Demonstration of a lack of synergistic effect of rotavirus with other diarrheal pathogens on severity of diarrhea in children.

Authors:  L E Unicomb; S M Faruque; M A Malek; A S Faruque; M J Albert
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

5.  Decline in Emergency Department Visits for Acute Gastroenteritis Among Children in 10 US States After Implementation of Rotavirus Vaccination, 2003 to 2013.

Authors:  Minesh P Shah; Jacqueline E Tate; Claudia A Steiner; Umesh D Parashar
Journal:  Pediatr Infect Dis J       Date:  2016-07       Impact factor: 2.129

6.  Protective efficacy of a sulfated sialyl lipid (NMSO3) against human rotavirus-induced diarrhea in a mouse model.

Authors:  Kazuo Takahashi; Kazutaka Ohashi; Yurika Abe; Shuichi Mori; Koki Taniguchi; Takusaburo Ebina; Osamu Nakagomi; Masaki Terada; Shiro Shigeta
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenic Escherichia coli.

Authors:  John K Crane; Tonniele M Naeher; Jacqueline E Broome; Edgar C Boedeker
Journal:  Infect Immun       Date:  2013-01-22       Impact factor: 3.441

8.  Sequential changes in small intestinal structure and function during rotavirus infection in neonatal rats.

Authors:  A F Salim; A D Phillips; J A Walker-Smith; M J Farthing
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

9.  Clinical Symptoms of Human Rotavirus Infection Observed in Children in Sokoto, Nigeria.

Authors:  B R Alkali; A I Daneji; A A Magaji; L S Bilbis
Journal:  Adv Virol       Date:  2015-11-25

10.  Relationship between asymptomatic rotavirus infection and jaundice in neonates: a retrospective study.

Authors:  Nu Ri Hwang; Jin Kyu Kim
Journal:  BMC Pediatr       Date:  2018-11-30       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.